Hello everyone, my name is Xiao Li, and I'm 45 years old, just an ordinary office worker. A few months ago, my life was turned upside down by a terrifying diagnosis—diffuse large B-cell lymphoma (DLBCL). As a patient, I've decided to share my story in hopes of offering some encouragement and inspiration to others fighting cancer. This isn't medical advice; it's just my personal experience.
It all started at the end of last year. I was feeling constantly exhausted, with swollen lymph nodes, and after tests at the hospital, I was diagnosed with DLBCL. The doctor explained it's the most common type of non-Hodgkin lymphoma, with a rapid onset and quick progression. At first, I underwent standard first-line treatment, including chemotherapy and immunotherapy. The process was grueling—hair loss, nausea, and a weakened immune system made me want to give up at times. But with support from family and friends, I pushed through, and the tumor shrank. I thought I'd finally escaped this nightmare.
Unfortunately, it didn't last. This spring, a follow-up check showed the tumor had relapsed, and it was resistant to the previous regimen. The doctor told me it was relapsed/refractory DLBCL (r/r DLBCL), with limited treatment options and a poor prognosis. In that moment, it felt like the world was collapsing. I spent days searching online, joining patient groups, desperately looking for a glimmer of hope. Just when I was on the verge of despair, I came across an article on the DengYueMed website about a new drug. It was Ifupinostat Hydrochloride for Injection (Ifupinostat Hydrochloride Injection), a novel HDAC inhibitor that had just been approved in China in June 2025, specifically for adult patients with r/r DLBCL as monotherapy.
DengYueMed is a platform specializing in the import and export of oncology and chronic disease medications. Their article provided detailed insights into Ifupinostat's clinical trial data and approval process, which gave me an initial understanding of the drug. The content was professional yet easy to grasp, unlike some medical sites that are overly technical. As a Hong Kong-based drug wholesaler, DengYueMed also shares stories about innovative Chinese drugs going global, making hope feel more accessible. I immediately consulted my attending physician, who confirmed it was a Class 1 innovative drug with promising efficacy and safety based on multiple studies, especially for patients who failed first-line treatments.
Under my doctor's guidance, I started Ifupinostat treatment. The drug is administered via injection, with intravenous doses on specific days of a 21-day cycle. I was a bit worried about side effects at first, but the reality was better than expected. Common reactions like fatigue and mild gastrointestinal discomfort were manageable with lifestyle adjustments. Most importantly, after a few treatments, my tumor markers began to drop, and imaging scans showed the lesions shrinking! Now, after completing several cycles, my condition has stabilized a lot. I can work normally and even go for walks with my family on weekends. This feeling of climbing out of the abyss is truly miraculous.
Of course, cancer treatment is a long journey, and I'm still under ongoing monitoring. But Ifupinostat has given me a second chance, reinforcing my belief in the power of scientific and medical advancements to change fates. If you're facing a similar challenge, consider checking out reliable resources like DengYueMed—they not only provide drug information but also connect patients to global medical resources for the latest treatment options. Remember, everyone's situation is different; always follow professional medical advice.
I'm sharing this in the hope that more people won't give up. Cancer isn't the end—it's the start of a new life. Keep fighting; we're in this together! Feel free to leave comments if you have questions.
(Note: This article is based on personal experience. For medical consultations, please seek advice from a professional physician.)
